Poster Presentations S59 Previously, we have established one e library by introducing 8 randomized sequences in upper stem and selected out a series of RNA aptamers with higher affinity to P protein based on the in vitro SELEX in duck hepatitis B virus (DHBV) system. Interestingly, we observed that only part of these stronger binders support priming. In order to explore structural determinants within e, all selected aptamers were subjected to RNA structural mapping. We found that an undamaged bulge is essential for initiating priming. On the other hand, our study demonstrates that the stronger binders with damaged bulge structure are able to be potentially used as decoys for antiviral therapy by interfering with the protein-priming process of wild type DHBV.
One of the important factors in safety of blood transfusion is to use an additional sensitive screening test to identify blood-born infective agents (like HBV). Although HBsAg screening reduces the risk of HBV transmission, but HBsAg negative blood donors may yet transmit HBV infection. The aim of this study was to assess the possibility of using anti-HBc as a screening test to improve the detection rate of HBV infection in donated blood in city of Rasht, North of Iran. A total of 2,041 blood samples with negative result for HBsAg, Anti-HCV, Anti-HIV I, II and RPR were collected and used to detect anti-HBc Ab. If the result of anti-HBc was positive, the samples were evaluated for HBV DNA detection. DNA extraction was done by using a commercial DNA extraction kit (Qiagen) and analyzed using a commercial quantitative real-time PCR kit (artus HBV LC PCR Kit). The positive sample was rechecked with a reliable and sensitive homemade PCR kit. The prevalence of anti-HBc Ab positive was 78/2041 (0.038%) by total anti-HBc Ab kit. One out of 78 anti-HBc Ab positive sample was positive for HBV DNA when was checked by real-time PCR and re-checked by homemade kit. This study showed that the anti-HBc Ab positivity is lower than many parts of Iran in Rasht. As anti-HBc Ab positive blood donors may be a potential source of HBV transmission further study for evaluation of HBV DNA in anti-HBc positive blood units is strongly recommended. Background and Aims: The experimentation of antivirals, new vaccine formulations and adjuvanted antigens, able to elicit a specifically targeted cellular response or to interfere with viral replication to break tolerance, is crucial for immunotherapeutic approaches of Hepatitis B Virus (HBV) infection. In this study we have applied the well recognized preclinical model of the HBV, the Woodchuck (Marmota monax) chronically infected from Woodchuck Hepatitis Virus (WHV) with the aim to investigate the neutralization and antiviral effects of Immune Genic Complex (IGC) composed by preS/S antibodies and WHV particles in healthy and in WHV chronically infected animals. Methods: The characterized and quantified neutralization mixture or IGC, was intravenously and intradermically administered to four WHV negative and five WHV chronic carriers. One animal was used as infection control. Electro-chemi-luminescence immuno-assay (Elecsys, Roche Molecular Diagnostics) to detect antibody to WHV core antigen (WHcAb) and WHV "e" antigen (WHeAb), and WHV "e" antigen (WHeAg) was used. WHV Real-Time PCR was applied to determine the viral load every two weeks after IGC administrations and PBMc proliferation assays was performed making use of Core and PreS/S HBV regions epitopes. Results: The IGC administration obtained with the lowest preS/S antibody amount (2.5 mIU) showed, in WHV negative woodchucks, better neutralization effects in terms of WHeAg and viral load concentrations in all treated animals in respect to the controls. The IGC administration in WHV chronic carriers induced strong antiviral effect in three out of five animals. The viral phylogenetic analysis (MEGA 4 program) of PreS/S region showed, in one animal, significant variation during follow up. Conclusions: This newly designed experimental protocol will be at the basis for further developments in the field of improvement of antigenic adjuvancy and of therapeutic vaccines formulations.
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PP-014 Entecavir treatment of chronic hepatitis B
patients who are exposed to lamivudine R. Behal *, P. Upadhyay, P. Srivastava, T.S. Negi, G. Choudhuri. Department of Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow, 226014, India Background and Aims: In treatment of naive chronic hepatitis B (CHB) patients, Entecavir shows good long term viral suppression and low rate of development of resistance. Its role in patients of CHB, who are exposed to lamivudine therapy, is not clear. We studied the efficacy of Entecavir in this group of patients. Methods: Ten patients who showed breakthrough during lamivudine therapy, were treated with Entecavir (1 mg/day). The dose was modified in patients of renal failure as required. HBV DNA quantitative levels were done 3 monthly to assess adequacy and duration of viral suppression. Assessment for Entecavir resistance defined as decline of <1 log 10 copies/ml in 12 weeks or increase in HBV DNA by 1 or 2 log levels were the primary end points. Results: Of 10 patients (8 male; 8 HBeAg positive, 5 with compensated Liver Cirrhosis) who received Entecavir, phenotypic resistance to Entecavir was seen in 5 (50%) over a mean period of 12 ± 4.58 months. Of these 5, 4 were on 1.0 mg/day dose. Median follow up of patients was: 11.5 ± 4.13 months (1.0 mg dose) and 9.25 ± 4.78 months (0.5 mg dose). Four of six patients (66%) who received 1 mg/day Entecavir, developed resistance over a median follow up of 11 months. Of the four patients who received 0.5 mg/day entecavir, one (25%) developed resistance over follow up of 15 months. Conclusions: Entecavir therapy in Lam resistant CHB patients was associated with a high rate of inadequate viral suppression and development of resistance. The dose of Entecavir (0.5 or 1.0) did not seem to have much effect in this group of patients.
PP-015 Management of chronic hepatitis B (CHB)
antiviral resistance the Asia experience Conclusion: Antiviral resistance is a major concern among physicians in Asia, especially during long-term therapy. While access to direct resistance testing is limited in most countries, indirect methods are widely used to guide CHB management decisions. In choosing an oral antiviral to initiate therapy, resistance profile of antiviral is a crucial factor to consider since drug resistance compromises clinical benefit and incurs additional cost. Objective: This paper is an attempt to do research on the cloning characteristics of the CDR3-distinct of the TCR Vbgene of the CD8+T cell of the HBV infected person. Methods: The PCR approach of poly-primer is applied and meanwhile the many pieces of the CDR3-distinct of the TCR Vb gene are amplified. HR-Agarose Gel Electrophoresis is employed to detect the cloning characteristics. Result: The HBV infected person's cloning of the TCR Vb9 and Vb14 of the CD8+T cell is obviously higher than the normal control group (p < 0.01). Conclusion: The HBV infected person has the cloning changes of the TCR VbandVb14 of the CD8+T cell, which have an effect on the mediating of the Liver Injury.
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